, -/-ob/ob:GIPR , , , , ob/ob
For the research context it is key for understanding why amylin analogs do not develop tolerance with chronic use (unlike many other anti-obesity molecules)
In fact, we ran clinical trials with both oral semaglutide and oral tirzepatide, and the results looked no better than placebo for weight loss
However, doses of 120mg twice daily were shown to be more associated with the production of reduced appetite, dyspepsia and dizziness
Other Factors to Consider Underlying Health Conditions: Conditions like diabetes, heart disease, and obesity can cause ED independently of medication
Reduced Inflammation Mounjaro-induced weight loss can lower systemic inflammation - a major driver of dysmenorrhoea (painful periods)